Zhang XH, Yuan GP, Chen TL. Clinical effect of methimazole combined with selenium in the treatment of toxic diffuse goiter in children. World J Clin Cases 2022; 10(4): 1190-1197 [PMID: 35211552 DOI: 10.12998/wjcc.v10.i4.1190]
Corresponding Author of This Article
Xiao-Hong Zhang, MD, Doctor, Department of Pediatric Endocrinology, Quanzhou Women and Children’s Hospital, No. 700 Fengze Street, Quanzhou 362000, Fujian Province, China. zhangxiaohong2109@163.com
Research Domain of This Article
Pediatrics
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 6, 2022; 10(4): 1190-1197 Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1190
Clinical effect of methimazole combined with selenium in the treatment of toxic diffuse goiter in children
Xiao-Hong Zhang, Gao-Pin Yuan, Ting-Li Chen
Xiao-Hong Zhang, Gao-Pin Yuan, Ting-Li Chen, Department of Pediatric Endocrinology, Quanzhou Women and Children’s Hospital, Quanzhou 362000, Fujian Province, China
Author contributions: Zhang XH, Yuan GP, and Chen TL designed and performed the study; Zhang XH, Yuan GP, and Chen TL analyzed the data; all authors contributed to the writing and revising of the manuscript.
Institutional review board statement: This study was approved by the Ethics Committee of the Quanzhou Maternal and Child Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: No conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Hong Zhang, MD, Doctor, Department of Pediatric Endocrinology, Quanzhou Women and Children’s Hospital, No. 700 Fengze Street, Quanzhou 362000, Fujian Province, China. zhangxiaohong2109@163.com
Received: October 22, 2021 Peer-review started: October 22, 2021 First decision: November 17, 2021 Revised: December 1, 2021 Accepted: December 22, 2021 Article in press: December 22, 2021 Published online: February 6, 2022 Processing time: 94 Days and 7.5 Hours
Core Tip
Core Tip: Anti-thyroglobulin (thyroglobulin antibody, TRAb) is a common antibody in the sera of children with autoimmune thyroid disease, and anti-thyroid peroxidase antibody (thyroid peroxidase antibody, TPOAb) is an indicator closely related to thyroid immune damage. In this study, 103 children with Graves’ disease treated in our hospital were selected and divided into a traditional group and a combined group according to treatment method to explore the therapeutic effects of the two methods and to detect changes in serum TRAb and TPOAb levels of the two groups of children before and after treatment. The clinical efficacy of the combined treatment provides a solid theoretical foundation for the clinical diagnosis and treatment of Graves.
